| YANG Yong-qiang,FENG Lin-chun,JIA Bao-qing,QU Bao-lin,MA Lin,LIU Hong-yi,WANG Yun-lai,GE Rui-gang,CHEN Jing,LAN Yu-ling,WANG Jing.Preliminary results of the prospective clinical trial of preoperative concomitant boost intensity-modulated radiotherapy in locally advanced rectal cancer[J].Chinese Journal of Radiological Medicine and Protection,2013,33(5):512-515 |
| Preliminary results of the prospective clinical trial of preoperative concomitant boost intensity-modulated radiotherapy in locally advanced rectal cancer |
| Received:March 23, 2013 |
| DOI：10.3760/cma.j.issn.0254-5098.2013.05.014 |
| KeyWords:Rectal cancer Intensity-modulated radiation therapy Capecitabine |
| FundProject: |
| Author Name | Affiliation | E-mail | | YANG Yong-qiang | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | | | FENG Lin-chun | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | 301flc@163.com | | JIA Bao-qing | 100853 北京, 解放军医学院肿瘤学系 解放军总医院肿瘤外科 | | | QU Bao-lin | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | | | MA Lin | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | | | LIU Hong-yi | 100853 北京, 解放军医学院肿瘤学系 解放军总医院肿瘤外科 | | | WANG Yun-lai | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | | | GE Rui-gang | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | | | CHEN Jing | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | | | LAN Yu-ling | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | | | WANG Jing | Department of Radiation Oncology, People's Liberation Army General Hospital, Beijing 100853, China | |
|
| Hits: 3145 |
| Download times: 2619 |
| Abstract:: |
| Objective To evaluate the feasibility, safety, and short-term efficacy of preoperative capecitabine and simultaneous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) in patients with locally advanced rectal cancer. Methods Between August 2012 and May 2013, a total of 13 patients with resectable stage Ⅱ or Ⅲ rectal cancer received capecitabine (825 mg/m2 P.O, twice a day, 5 d/week for 5 weeks) and SIB-IMRT delivering 56.25 Gy (2.25 Gy/fraction) to the gross tumor while simultaneously delivering 50 Gy (2.0 Gy/fraction) to the regional lymph nodes and areas at risk for harboring microscopic disease. Total mesorectal excision was scheduled 4 to 8 weeks after the completion of chemoradiation. The primary endpoints included pathological complete response rate (ypCR), tumor downstaging, toxicity and postoperative complications. The secondary endpoint included the rate of sphincter-sparing surgery. Results All patients completed chemoradiation with strict compliance to the protocol schedule and then went on to surgical resection. Three patients had no residual tumor in the surgical specimen. Downstaging of the primary tumor and lymph nodes was observed in 9 and 4 patients, respectively. Grade 1 or 2 toxicities included leucopenia, thrombocytopenia and diarrhea. One patient developed vesical fistula after surgery. Ten patients underwent sphincter-sparing procedures. Conclusions Preoperative chemoradiation with capecitabine and SIB-IMRT can be safe and well tolerated for patients with locally advanced rectal cancer and the short term outcomes could be promising. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
